Changes in HIV antiretroviral prescribing practices in the United States

Int J STD AIDS. 2020 Jan;31(1):22-29. doi: 10.1177/0956462419880127. Epub 2019 Dec 2.

Authors

Quan M Vu¹, R Luke Shouse¹, Kathleen Brady², John T Brooks¹, John Weiser¹

Affiliations

¹ Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
² AIDS Activities Coordinating Office, Philadelphia Department of Public Health, Philadelphia, PA, USA.

PMID: 31793389
DOI: 10.1177/0956462419880127

No abstract available

Keywords: Antiretroviral agent; HIV integrase inhibitor; prescription; protease inhibitor; reverse transcriptase inhibitor.

Publication types

Research Support, U.S. Gov't, P.H.S.

MeSH terms

Antiretroviral Therapy, Highly Active*
Drug Prescriptions / statistics & numerical data*
HIV Infections / drug therapy*
HIV Protease Inhibitors / therapeutic use*
HIV Reverse Transcriptase / therapeutic use*
Humans
Medical Records
Practice Patterns, Physicians' / statistics & numerical data
Practice Patterns, Physicians' / trends*
Prevalence
Reverse Transcriptase Inhibitors / therapeutic use*
United States

Substances

HIV Protease Inhibitors
Reverse Transcriptase Inhibitors
HIV Reverse Transcriptase